CBD and medications: interactions, precautions, and what science says

CBD can change how your body processes certain medications. In most cases, this is not an absolute contraindication, but it is information your doctor or pharmacist should know before you start. This page explains the mechanism, the medications concerned, and the practical precautions to take.

When you take a medication, your liver breaks it down for elimination. This process is largely carried out by a family of enzymes called cytochrome P450 (CYP450). These enzymes are estimated to be involved in the metabolism of over 80% of prescription drugs.

Once absorbed, CBD interacts with several of these enzymes, mainly by inhibiting them, meaning it slows down their activity. As a result, medications that rely on these enzymes for elimination accumulate more in the blood, sometimes at higher levels than expected. This is called a drug interaction.

The enzymes most affected by CBD, in order of observed inhibition intensity, are: CYP2E1, CYP2C19, CYP2B6, CYP2D6, CYP3A4, CYP2C9, and CYP1A2. The latter four, particularly CYP3A4 and CYP2C19, are among the most important in the metabolism of common drugs, which explains why the issue of interactions deserves to be taken seriously.

Available clinical data allow for distinguishing several levels of risk. Here are the classes of medications for which interactions with CBD have been documented, from the most to the least well-established.

Anticoagulants, documented high risk

Warfarin (Coumadin) is the most documented case. CBD inhibits the CYP2C9 enzyme, primarily responsible for warfarin metabolism. Several published clinical cases report an elevation of INR (coagulation indicator) and an increased risk of bleeding during concomitant use. Warfarin has a very narrow therapeutic index: a small variation in its blood concentration can have serious consequences.

For newer anticoagulants like apixaban or rivaroxaban, clinical data are still limited. However, as these molecules also pass through hepatic pathways, an interaction risk is plausible and should be discussed with your doctor.

Antiepileptics, the most clinically proven interaction

Paradoxically, this is the area where data is most robust, because CBD itself is approved as an antiepileptic drug (Epidiolex) in some countries, and its interactions are therefore documented in official clinical trials.

Clobazam is the reference case: CBD inhibits CYP2C19, which significantly increases the plasma levels of clobazam and its active metabolite (N-desmethylclobazam), sometimes by as much as 500% according to studies. A dose adjustment is systematically necessary in this context.

Valproate (Depakine) poses another type of problem: its association with CBD has been linked to elevated liver enzymes in Epidiolex clinical data. The European Food Safety Authority (EFSA) explicitly highlighted this risk in its 2025 statement.

Other antiepileptics metabolized by CYP3A4 or CYP2C19 (phenytoin, carbamazepine, stiripentol, topiramate) may also be affected to varying degrees.

Immunosuppressants, documented risk in transplant patients

Cyclosporine, tacrolimus, and everolimus, all metabolized by CYP3A4, have been the subject of case reports of accumulation to dangerous levels in transplant patients taking CBD. These medications also have a narrow therapeutic index: too little means rejection risk; too much means toxicity. If you are a transplant recipient and are taking any of these medications, CBD use must be imperatively discussed and medically monitored.

Central Nervous System Depressants

Benzodiazepines (diazepam, alprazolam, clonazepam...), opioids, and barbiturates may have their sedative effects amplified in the presence of CBD. The interaction can manifest as excessive drowsiness, respiratory depression, or prolonged impairment of cognitive functions. The mechanism combines enzymatic inhibition and potentially a direct additive effect on the central nervous system.

Statins and Cardiovascular Treatments

Certain statins (atorvastatin, simvastatin) and antiarrhythmics (amiodarone, quinidine) pass through CYP3A4 and may see their plasma concentrations increase in the presence of CBD. The concrete clinical risk depends on the specific molecule and the CBD dosage used.

Antidepressants and Antipsychotics

Several antidepressants (sertraline, fluoxetine, certain tricyclics) and antipsychotics are metabolized by CYP2D6 or CYP3A4. Interactions with CBD are theoretically possible and have been reported in individual cases. Vigilance is advised, although clinical data do not allow for establishing a risk as precise as for anticoagulants or antiepileptics.

Medications with a narrow therapeutic index: maximum vigilance

Regardless of the class, the medications at highest risk are those where the effective dose and the toxic dose are close. Besides warfarin and immunosuppressants already mentioned, this includes digoxin, lithium, certain antiretrovirals, and theophylline.

The presence of a potential interaction does not mean you cannot take CBD. In many cases, medical monitoring and a medication dose adjustment allow for safe use of both. What it means is that this decision should not be made alone, without informing your doctor or pharmacist.

Here are the situations that require a medical discussion before any CBD use:

• You are taking an anticoagulant, regardless of the molecule.
• You are undergoing antiepileptic treatment.
• You are a transplant recipient and on immunosuppressants.
• You are taking a medication for which your doctor or pharmacist has already asked you to avoid grapefruit.
• You are taking a medication with a narrow therapeutic index, meaning regular monitoring of your blood level is necessary.
• You are taking benzodiazepines or opioids.

This page is for informational and educational purposes only. It does not replace medical or pharmaceutical advice. If you are taking prescription medications, consult your doctor or pharmacist before starting to use CBD.